tetano
Editor, Senior Moderator
Curr Protoc Microbiol
. 2020 Sep;58(1):e108.
doi: 10.1002/cpmc.108.
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening
Fatima Amanat[SUP] 1 2 [/SUP], Kris M White[SUP] 2 3 [/SUP], Lisa Miorin[SUP] 2 3 [/SUP], Shirin Strohmeier[SUP] 2 [/SUP], Meagan McMahon[SUP] 2 [/SUP], Philip Meade[SUP] 1 2 [/SUP], Wen-Chun Liu[SUP] 2 3 [/SUP], Randy A Albrecht[SUP] 2 3 [/SUP], Viviana Simon[SUP] 2 3 4 [/SUP], Luis Martinez-Sobrido[SUP] 5 [/SUP], Thomas Moran[SUP] 2 [/SUP], Adolfo Garc?a-Sastre[SUP] 2 3 4 6 [/SUP], Florian Krammer[SUP] 2 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. ? 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.
Keywords: COVID-19; COVID19; SARS-CoV-2; antivirals; medium-throughput screening; microneutralization; neutralization.
. 2020 Sep;58(1):e108.
doi: 10.1002/cpmc.108.
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening
Fatima Amanat[SUP] 1 2 [/SUP], Kris M White[SUP] 2 3 [/SUP], Lisa Miorin[SUP] 2 3 [/SUP], Shirin Strohmeier[SUP] 2 [/SUP], Meagan McMahon[SUP] 2 [/SUP], Philip Meade[SUP] 1 2 [/SUP], Wen-Chun Liu[SUP] 2 3 [/SUP], Randy A Albrecht[SUP] 2 3 [/SUP], Viviana Simon[SUP] 2 3 4 [/SUP], Luis Martinez-Sobrido[SUP] 5 [/SUP], Thomas Moran[SUP] 2 [/SUP], Adolfo Garc?a-Sastre[SUP] 2 3 4 6 [/SUP], Florian Krammer[SUP] 2 [/SUP]
Affiliations
- PMID: 32585083
- DOI: 10.1002/cpmc.108
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. ? 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.
Keywords: COVID-19; COVID19; SARS-CoV-2; antivirals; medium-throughput screening; microneutralization; neutralization.